Is evantumumab covered by medical insurance? What are the conditions and proportions of medical insurance reimbursement?

Amivantamab (amivantamab) is an anti-cancer drug launched in recent years. It is mainly used to treat patients with non-small cell lung cancer (NSCLC), especially EGFR mutation-positive and drug-resistant patients. This drug has attracted great attention due to its targeted properties and significant clinical effects. Although evantumumab has been on the domestic market for a short time, it has not yet been included in China's national medical insurance directory, so domestic patients cannot purchase the drug through medical insurance reimbursement.

Currently, evantumumab is not included in China’s medical insurance catalog, which means that patients cannot enjoy medical insurance reimbursement when purchasing the drug. This poses a great challenge to the financial burden of patients, especially the relatively high price of this drug. According to market information, the original drug of evantuzumab is priced at about 10,000 yuan in Hong Kong. In China, patients may face full out-of-pocket expenses that cannot be covered by medical insurance. Therefore, when considering purchasing this drug, patients need to budget the cost in advance and confirm the drug price with the medical institution or pharmacy.

Since evantumumab is not yet covered by medical insurance in China and the supply in domestic pharmacies may be limited, many patients choose to purchase the drug through overseas channels. The original version of the drug in Hong Kong, China, has been launched locally with a price of approximately 10,000 yuan. Patients can purchase it through Hong Kong pharmacies or legal cross-border e-commerce platforms. However, since cross-border purchases involve taxes, logistics and other issues, patients need to consider these additional costs as well as the transportation and safety of the drugs when purchasing.

Although evantumumab is currently not included in the medical insurance catalog, with the promotion of this drug in the domestic market and the accumulation of clinical data, it may be included in the medical insurance in the future. Especially for patients with certain types of cancer, if the drug can provide a significant survival benefit, the possibility of national health insurance negotiations will increase. Patients should stay tuned to relevant policy developments and communicate with doctors and pharmacy staff to obtain the latest medical insurance information on drugs. At the same time, patients can also learn from the medical insurance department about the specific inclusion conditions and related processes in case of emergency.

Reference materials:https://www.rybrevant.com/